2. UroToday Home
  3. Conference Highlights
  4. 11th International Symposium on Targeted Alpha Therapy, TAT-11

TAT-11: Has the Dream Come True? A Retrospective Look at the Development of Alpha Therapy and its Promise for the Future

Ottawa, ON, Canada (UroToday.com) Dr. Ruth began reviewing some of the early isotope production for use in alpha therapy. He concentrated on At211 beginning with Brookhaven National Lab production with double charge exchange: Bi(pi+,pi-)At211. The At211 was collected in a Te colloid, then separated. Moving on to more modern production, TRIUMF produced At211 via alpha bombardment of Bi: Bi209(alpha, 2n)At211 or via electron capture decay of Rn211.

The TRIUMF Isotope Separation On-LineTESOLOL can produce up to 0.027 mCi/hr. Rn211 can be isolated by mass separation from spallation products of Uranium. Dr, Ruth emphasized the need to select alpha emitters that have a good chance for ending up in a clinical treatment portfolio. For the most promising, there is a critical need for developing robust, reliable production methods.


Presented by: Thomas Ruth, PhD, Emeritus Senior Research Scientist, TRIUMF, Vancouver, Canada


Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10)  April 1 - April 4, 2019 - Ottawa, ON, Canada